Cytomegalovirus viremia, pneumonitis, and tocilizumab therapy

Emerging Infectious Diseases

Volumn 17, Issue 4, 2011, Pages 754-756

  van Duin, David ^a   Miranda, Cyndee ^a   Husni, Elaine ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ETANERCEPT; GANCICLOVIR; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6 RECEPTOR; LEVOFLOXACIN; METHOTREXATE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; TOCILIZUMAB; VALGANCICLOVIR; VANCOMYCIN; VIRUS DNA;

ADULT; CASE REPORT; CLINICAL FEATURE; COUGHING; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DIARRHEA; DRUG FEVER; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEVER; HEMATOCRIT; HUMAN; INFECTION RISK; KIDNEY FAILURE; LETTER; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; NAUSEA; NAUSEA AND VOMITING; PANCYTOPENIA; PNEUMONIA; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIREMIA; WHEEZING;

EID: 79953709379     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1706.101057     Document Type: Letter

References (10)

1. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761-9. DOI: 10.1002/art.20303
2. European Medicines Agency. Actemra (tocilizumab): summary of product characteristics, 2009 [cited 2009 Mar 23]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf
3. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010;6:165-74. DOI: 10.1038/nrrheum.2009.279
4. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC. Cytokines and immunity to viral infections. Immunol Rev. 1997;159:119-35. DOI: 10.1111/j.1600-065X.1997.tb01011.x
5. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56:2896-904. DOI: 10.1002/art.22808
6. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-80. DOI: 10.1002/ art.23940
7. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987-97. DOI: 10.1016/S0140-6736(08)60453-5
8. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti- IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68:1580-4. DOI: 10.1136/ard.2008.092866
9. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet. 2008;371:998-1006. DOI: 10.1016/S0140-6736(08)60454-7
10. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20:222-32. DOI: 10.1007/s10165-010-0279-5